Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totaling 1,609,679 shares, a decrease of 37.4% from the May 31st total of 2,572,499 shares. Based on an average daily volume of 1,385,421 shares, the short-interest ratio is currently 1.2 days. Approximately 1.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

CNTA has been the topic of a number of recent analyst reports. Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a research note on Monday, April 13th. Stephens lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA remained flat at $40.50 during trading on Friday. The stock has a 50-day simple moving average of $39.83 and a 200 day simple moving average of $32.02. The company has a market cap of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals has a 12 month low of $12.74 and a 12 month high of $40.56. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Research analysts forecast that Centessa Pharmaceuticals will post -1.65 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. grew its holdings in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the period. Wells Fargo & Company MN raised its position in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $100,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.